Home » Archivi Autore: tifwp

Archivi Autore: tifwp

Sickle Cell Disease Update

CRISPR gene editing (SCD)   Update: 30 May 2019 No update available.   Update: 29 March 2019 The Phase 1/2 Study in Sickle Cell Disease (SCD) is an open-label trial aiming to assess the safety and efficacy of a single dose of CTX001 in patients ages 18 to 35 with ...

Leggi Articolo »


  Update: 30 May 2019  Apotransferrinhas a physiological role in the transportation and distribution of iron among the body organs. Apotrasferrin has received orphan drug designation from EMA A proof of concept study in the Netherlands will begin in the second half of 2019 lasting 16 weeks with a maximum ...

Leggi Articolo »

International Thalassaemia Day 2019 – Get inspired, get involved!

This is how this year’s voting results were shaped: Universal access to quality thalassaemia healthcare services: Building bridges with and for patients (Winning theme, 196 votes) Patients’ voice at the frontline: Advocating for a better future in thalassaemia care and management (112 votes) The globalization of thalassaemia – Common challenges ...

Leggi Articolo »

Ferroportin inhibitors

VIT-2763   Update: 30 May 2019 No update available.    Update: 01 February 2019 A randomized, controlled, multi-centred phase 2 proof-of-concept trial will begin in the second half of 2019 to assess the effectiveness of the oral ferroportin inhibitor (VIT-2763) on iron overload in β-thalassaemia patients. Phase 1 trials have ...

Leggi Articolo »


  Update: 30 May 2019 No update available.   Update: 29 March 2019 SLN124 has been submitted to the UK Medicines and Healthcare Products Regulatory Agency (MHRA). Subject to approval from the MHRA, Silence intends to begin a Phase I/II First-in-Human study in ß -Thalassemia and MDS patients, with the ...

Leggi Articolo »

Banca dati epidemiologica sulle malattie da emoglobina

Il progetto epidemiologico della TIF si concentra sulla raccolta di informazioni riguardanti le percentuali di soggetti portatori, le nascite premature e lo stato attuale delle strategie di controllo dell’emoglobinopatia nei sistemi sanitari dei paesi membri della TIF per β- e α-talassemia, HbE e anemia falciforme, le cui combinazioni costituiscono l’obiettivo ...

Leggi Articolo »